{"id":"W2223384622","doi":"10.1158/1538-7445.sabcs14-p1-13-07","title":"Abstract P1-13-07: A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Hazard ratio; Breast cancer; Tolerability; Antiestrogen; Aromatase inhibitor; Oncology; Clinical endpoint; Cancer; Population; Adverse effect; Randomized controlled trial; Tamoxifen; Gynecology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001353014,0.001138078,0.001485422,0.0003896798,0.0003331886,0.0004769401,0.0007589643,0.0008363317,0.004447125],"category_scores_gemma":[0.0007110409,0.000386059,0.001086328,0.0003409118,0.001039877,0.0004739991,0.0002568301,0.001815623,0.0006944911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006622984,"about_ca_system_score_gemma":0.001999167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001533752,"about_ca_topic_score_gemma":0.003431679,"domain_scores_codex":[0.9997683,0.000102905,0.00001337661,0.00004433145,0.00002576722,0.00004537011],"domain_scores_gemma":[0.9995912,0.00007329166,0.00007971273,0.00004283557,0.0000330153,0.0001799871],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8702796,0.04160933,0.003921594,0.0008192299,0.001328282,0.000108358,0.0002031517,0.0006555555,0.03077552,0.0001989574,0.001587273,0.04851318],"study_design_scores_gemma":[0.645496,0.3383777,0.01036446,0.00002095704,0.0007590225,0.00007366959,0.00003982713,0.0004289803,0.003336667,0.00009661352,0.000984567,0.00002162718],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954555,0.0008272294,0.0002449723,0.0002320607,0.00005891294,0.001751221,0.0005890388,0.00004897735,0.0007920708],"genre_scores_gemma":[0.9926695,0.0009320904,0.0008493208,0.0004768776,0.00009948044,0.001843999,0.0008695929,0.00001411196,0.002244939],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004447125,"threshold_uncertainty_score":0.01487714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08213161146119569,"score_gpt":0.4780968770809828,"score_spread":0.3959652656197871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}